fashion -WSS

fashion

author：Wikipedia 2025-09-03 05:38:07 - browse：54498

George Yancopoulos on the 2024 Breakthrough Summit East stage. — George Yancopoulos on the 2024 Breakthrough Summit East stage STAT

George Yancopoulos is in touch with his teenage self.

After 35 years as head scientist at Regeneron Pharmaceuticals, Yancopoulos has led the development of 12 approved medicines, turning a once-fledgling company into the $100 billion global drugmaker it is today. And you can trace a straight line back to the childhood fascination with science he fostered growing up in Woodside, Queens.

“My high school science project was about regenerating neurons, and ‘Regeneron’ is a contraction of ‘regenerating neurons,’” Yancopoulos said at the STAT Summit East on Thursday. “In some ways I’m still working on my high school science project.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Eli Lilly’s Mounjaro succeeds in second weight

knowledge

WSS

Biden administration plans revamp of organ transplant system

AltruBio raises $225 million to develop ulcerative colitis drug

Eli Lilly’s Mounjaro succeeds in second weight

Primary care doctor shortage won't be solved by free med school tuition

Sea level rise could wash away turtle breeding grounds around the world, researchers say

AI for drug discovery: Experts on separating hype from reality

explore

fashion

entertainment

Medicare proposal to cover medical devices draws a mixed reaction

Deliver public health messages at the right time

How one medical school became remarkably diverse

Crowdfunding for medical bills sidesteps core problem, author says

After affirmative action ruling, medical educators look to 'holistic review'

Mom launches Girl Scout troop for LGBTQ youth in Texas

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Xenotransplantation trials will require adjusting expectations, experts say

United colonoscopy coverage change 'may cost lives,' doctors say

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

leisure time

Has Bernie Sanders reached the limit of his pharma bullying effort?

Bispecific antibodies are next new thing in cancer immunotherapy